Skip to Content

Generic Absorica Availability

Absorica is a brand name of isotretinoin, approved by the FDA in the following formulation(s):

ABSORICA (isotretinoin - capsule;oral)

  • Manufacturer: RANBAXY
    Approval date: August 15, 2014
    Strength(s): 25MG, 35MG

Has a generic version of Absorica been approved?

No. There is currently no therapeutically equivalent version of Absorica available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Absorica. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Pharmaceutical semi-solid composition of isotretinoin
    Patent 7,435,427
    Issued: October 14, 2008
    Inventor(s): Vanderbist; Francis & Servais; Cecile & Baudier; Philippe
    Assignee(s): Galephar M/F
    An oral pharmaceutical composition of isotretinoin containing at least two lipidic excipients, one of them being hydrophilic (i.e. having an HLB value superior or equal to 10), the other being an oily vehicle.
    Patent expiration dates:
    • September 21, 2021
      ✓ 
      Drug product
  • Pharmaceutical semi-solid composition of isotretinoin
    Patent 8,367,102
    Issued: February 5, 2013
    Assignee(s): Galephar Pharmaceutical Research, Inc.
    An oral pharmaceutical composition of isotretinoin containing at least two lipidic excipients, one of them being hydrophilic (i.e. having an HLB value superior or equal to 10), the other being an oily vehicle.
    Patent expiration dates:
    • September 21, 2021
      ✓ 
      Patent use: TREATMENT OF A SKIN DISORDER
  • Pharmaceutical semi-solid composition of isotretinoin
    Patent 8,952,064
    Issued: February 10, 2015
    Assignee(s): Galephar Pharmaceutical Research, Inc.
    An oral pharmaceutical composition of isotretinoin containing at least two lipidic excipients, one of them being hydrophilic (i.e. having an HLB value superior or equal to 10), the other being an oily vehicle
    Patent expiration dates:
    • September 21, 2021
      ✓ 
      Drug product
  • Pharmaceutical semi-solid composition of isotretinoin
    Patent 9,078,925
    Issued: July 14, 2015
    Assignee(s): GALEPHAR PHARMACEUTICAL RESEARCH, INC.
    The invention relates to an oral pharmaceutical composition of isotretinoin at least two excipients, one of the excipients being a hydrophilic excipient having an HLB value greater than or equal to 10 and the other excipient being an oily vehicle. The oral pharmaceutical composition is substantially devoid of food effect as characterized by a dissolution profile wherein at least 70% of the oral pharmaceutical composition is dissolved after about four hours in a USP2 dissolution apparatus at a paddle speed of 100 rpm, and a dissolution media composed of 900 mL of pH 7.5 buffer containing 0.11% pancreatin, 4.7% cholic acid, 0.14% sodium dihydroxide phosphate and 0.5% sodium hydroxide at 37° C.
    Patent expiration dates:
    • September 21, 2021
      ✓ 
      Drug product
  • Pharmaceutical semi-solid composition of isotretinoin
    Patent 9,089,534
    Issued: July 28, 2015
    Assignee(s): Galephar Pharmaceutical Research, Inc.
    An oral pharmaceutical composition of isotretinoin containing at least two lipidic excipients, one of them being hydrophilic (i.e. having an HLB value superior or equal to 10), the other being an oily vehicle.
    Patent expiration dates:
    • September 21, 2021
      ✓ 
      Drug product

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
Hide